Skip to main content
ARROWHEAD PHARMACEUTICALS, INC. logo

ARROWHEAD PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · ARWR ISIN · US04280A1007 LEI · 549300O3CSB8T7OZ3D66 US Manufacturing
Open in API
Filings indexed 1,039 across all filing types
Latest filing 2014-02-13 Major Shareholding Noti…
Country US United States of America
Listing US ARWR

About ARROWHEAD PHARMACEUTICALS, INC.

https://arrowheadpharma.com/

Arrowhead Pharmaceuticals, Inc. is a biotechnology company that develops medicines to treat intractable diseases by silencing the genes that cause them. The company utilizes its proprietary RNA interference (RNAi) platform to create therapies that target disease pathways previously considered 'undruggable.' Arrowhead's development pipeline is focused on a broad range of therapeutic areas, including cardiometabolic, pulmonary, neuromuscular, and liver diseases. The company advances a portfolio of clinical-stage candidates designed to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
SCHEDULE 13G FILING
Major Shareholding Notification
2014-02-13 English
424B3
Capital/Financing Update Classification · 95% confidence The document is a 'Sticker Supplement to Resale Prospectus' filed pursuant to Rule 424(b)(3), which is a type of prospectus supplement related to securities offering. It updates information about selling shareholders and share amounts. This is a capital markets disclosure related to share issuance and resale, not a full report or financial statement. It is not an announcement of a report but a supplement to a prospectus, which fits best under Capital/Financing Update (CAP) as it relates to financing activities and share capital information. The document length is short and focused on shareholding changes in a resale prospectus context, confirming CAP classification.
2014-02-13 English
Regulatory Filings 2014
Regulatory Filings
2014-02-13 English
OPTION EXERCISE
Director's Dealing
2014-02-13 English
ARROWHEAD 13G
Major Shareholding Notification
2014-02-12 English
FORM 8-K
Remuneration Information Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated February 6, 2014. The content focuses on the approval of annual salary increases, cash bonuses for 2013, and equity awards for certain officers. It details compensation arrangements for named executives, including salary, bonuses, and stock option grants. The document references the company's 2013 Incentive Plan and includes exhibits related to stock option and restricted stock unit agreements. This type of disclosure about executive compensation adjustments and equity awards is characteristic of Remuneration Information filings. The document is not a full annual report, audit report, or earnings release, nor is it a proxy statement or a general regulatory filing. Therefore, the appropriate classification is Remuneration Information (DEF 14A). The confidence in this classification is high given the clear focus on executive compensation details.
2014-02-12 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.